Elevated β-catenin pathway as a novel target for patients with resistance to EGF receptor targeting drugs

Asuka Nakata, Ryo Yoshida, Rui Yamaguchi, Mai Yamauchi, Yoshinori Tamada, Andre Fujita, Teppei Shimamura, Seiya Imoto, Tomoyuki Higuchi, Masaharu Nomura, Tatsuo Kimura, Hiroshi Nokihara, Masahiko Higashiyama, Kazuya Kondoh, Hiroshi Nishihara, Arinobu Tojo, Seiji Yano, Satoru Miyano, Noriko Gotoh

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

There is a high death rate of lung cancer patients. Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are effective in some lung adenocarcinoma patients with EGFR mutations. However, a significant number of patients show primary and acquire resistance to EGFR-TKIs. Although the Akt kinase is commonly activated due to various resistance mechanisms, the key targets of Akt remain unclear. Here, we show that the Akt-β-catenin pathway may be a common resistance mechanism. We analyzed gene expression profiles of gefitinib-resistant PC9M2 cells that were derived from gefitinib-sensitive lung cancer PC9 cells and do not have known resistance mechanisms including EGFR mutation T790M. We found increased expression of Axin, a β-catenin target gene, increased phosphorylation of Akt and GSK3, accumulation of β-catenin in the cytoplasm/nucleus in PC9M2 cells. Both knockdown of β-catenin and treatment with a β-catenin inhibitor at least partially restored gefitinib sensitivity to PC9M2 cells. Lung adenocarcinoma tissues derived from gefitinib-resistant patients displayed a tendency to accumulate β-catenin in the cytoplasm. We provide a rationale for combination therapy that includes targeting of the Akt-β-catenin pathway to improve the efficacy of EGFR-TKIs.

Original languageEnglish
Article number13076
JournalScientific reports
Volume5
DOIs
Publication statusPublished - 2015 Aug 13
Externally publishedYes

Fingerprint

Catenins
Drug Delivery Systems
Epidermal Growth Factor Receptor
Protein-Tyrosine Kinases
Lung Neoplasms
Cytoplasm
Mutation
Transcriptome
Phosphotransferases
Phosphorylation
Mortality
gefitinib
Therapeutics
Genes

ASJC Scopus subject areas

  • General

Cite this

Nakata, A., Yoshida, R., Yamaguchi, R., Yamauchi, M., Tamada, Y., Fujita, A., ... Gotoh, N. (2015). Elevated β-catenin pathway as a novel target for patients with resistance to EGF receptor targeting drugs. Scientific reports, 5, [13076]. https://doi.org/10.1038/srep13076

Elevated β-catenin pathway as a novel target for patients with resistance to EGF receptor targeting drugs. / Nakata, Asuka; Yoshida, Ryo; Yamaguchi, Rui; Yamauchi, Mai; Tamada, Yoshinori; Fujita, Andre; Shimamura, Teppei; Imoto, Seiya; Higuchi, Tomoyuki; Nomura, Masaharu; Kimura, Tatsuo; Nokihara, Hiroshi; Higashiyama, Masahiko; Kondoh, Kazuya; Nishihara, Hiroshi; Tojo, Arinobu; Yano, Seiji; Miyano, Satoru; Gotoh, Noriko.

In: Scientific reports, Vol. 5, 13076, 13.08.2015.

Research output: Contribution to journalArticle

Nakata, A, Yoshida, R, Yamaguchi, R, Yamauchi, M, Tamada, Y, Fujita, A, Shimamura, T, Imoto, S, Higuchi, T, Nomura, M, Kimura, T, Nokihara, H, Higashiyama, M, Kondoh, K, Nishihara, H, Tojo, A, Yano, S, Miyano, S & Gotoh, N 2015, 'Elevated β-catenin pathway as a novel target for patients with resistance to EGF receptor targeting drugs', Scientific reports, vol. 5, 13076. https://doi.org/10.1038/srep13076
Nakata, Asuka ; Yoshida, Ryo ; Yamaguchi, Rui ; Yamauchi, Mai ; Tamada, Yoshinori ; Fujita, Andre ; Shimamura, Teppei ; Imoto, Seiya ; Higuchi, Tomoyuki ; Nomura, Masaharu ; Kimura, Tatsuo ; Nokihara, Hiroshi ; Higashiyama, Masahiko ; Kondoh, Kazuya ; Nishihara, Hiroshi ; Tojo, Arinobu ; Yano, Seiji ; Miyano, Satoru ; Gotoh, Noriko. / Elevated β-catenin pathway as a novel target for patients with resistance to EGF receptor targeting drugs. In: Scientific reports. 2015 ; Vol. 5.
@article{0ea35834288742f9b85a160d72f8acfa,
title = "Elevated β-catenin pathway as a novel target for patients with resistance to EGF receptor targeting drugs",
abstract = "There is a high death rate of lung cancer patients. Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are effective in some lung adenocarcinoma patients with EGFR mutations. However, a significant number of patients show primary and acquire resistance to EGFR-TKIs. Although the Akt kinase is commonly activated due to various resistance mechanisms, the key targets of Akt remain unclear. Here, we show that the Akt-β-catenin pathway may be a common resistance mechanism. We analyzed gene expression profiles of gefitinib-resistant PC9M2 cells that were derived from gefitinib-sensitive lung cancer PC9 cells and do not have known resistance mechanisms including EGFR mutation T790M. We found increased expression of Axin, a β-catenin target gene, increased phosphorylation of Akt and GSK3, accumulation of β-catenin in the cytoplasm/nucleus in PC9M2 cells. Both knockdown of β-catenin and treatment with a β-catenin inhibitor at least partially restored gefitinib sensitivity to PC9M2 cells. Lung adenocarcinoma tissues derived from gefitinib-resistant patients displayed a tendency to accumulate β-catenin in the cytoplasm. We provide a rationale for combination therapy that includes targeting of the Akt-β-catenin pathway to improve the efficacy of EGFR-TKIs.",
author = "Asuka Nakata and Ryo Yoshida and Rui Yamaguchi and Mai Yamauchi and Yoshinori Tamada and Andre Fujita and Teppei Shimamura and Seiya Imoto and Tomoyuki Higuchi and Masaharu Nomura and Tatsuo Kimura and Hiroshi Nokihara and Masahiko Higashiyama and Kazuya Kondoh and Hiroshi Nishihara and Arinobu Tojo and Seiji Yano and Satoru Miyano and Noriko Gotoh",
year = "2015",
month = "8",
day = "13",
doi = "10.1038/srep13076",
language = "English",
volume = "5",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Elevated β-catenin pathway as a novel target for patients with resistance to EGF receptor targeting drugs

AU - Nakata, Asuka

AU - Yoshida, Ryo

AU - Yamaguchi, Rui

AU - Yamauchi, Mai

AU - Tamada, Yoshinori

AU - Fujita, Andre

AU - Shimamura, Teppei

AU - Imoto, Seiya

AU - Higuchi, Tomoyuki

AU - Nomura, Masaharu

AU - Kimura, Tatsuo

AU - Nokihara, Hiroshi

AU - Higashiyama, Masahiko

AU - Kondoh, Kazuya

AU - Nishihara, Hiroshi

AU - Tojo, Arinobu

AU - Yano, Seiji

AU - Miyano, Satoru

AU - Gotoh, Noriko

PY - 2015/8/13

Y1 - 2015/8/13

N2 - There is a high death rate of lung cancer patients. Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are effective in some lung adenocarcinoma patients with EGFR mutations. However, a significant number of patients show primary and acquire resistance to EGFR-TKIs. Although the Akt kinase is commonly activated due to various resistance mechanisms, the key targets of Akt remain unclear. Here, we show that the Akt-β-catenin pathway may be a common resistance mechanism. We analyzed gene expression profiles of gefitinib-resistant PC9M2 cells that were derived from gefitinib-sensitive lung cancer PC9 cells and do not have known resistance mechanisms including EGFR mutation T790M. We found increased expression of Axin, a β-catenin target gene, increased phosphorylation of Akt and GSK3, accumulation of β-catenin in the cytoplasm/nucleus in PC9M2 cells. Both knockdown of β-catenin and treatment with a β-catenin inhibitor at least partially restored gefitinib sensitivity to PC9M2 cells. Lung adenocarcinoma tissues derived from gefitinib-resistant patients displayed a tendency to accumulate β-catenin in the cytoplasm. We provide a rationale for combination therapy that includes targeting of the Akt-β-catenin pathway to improve the efficacy of EGFR-TKIs.

AB - There is a high death rate of lung cancer patients. Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are effective in some lung adenocarcinoma patients with EGFR mutations. However, a significant number of patients show primary and acquire resistance to EGFR-TKIs. Although the Akt kinase is commonly activated due to various resistance mechanisms, the key targets of Akt remain unclear. Here, we show that the Akt-β-catenin pathway may be a common resistance mechanism. We analyzed gene expression profiles of gefitinib-resistant PC9M2 cells that were derived from gefitinib-sensitive lung cancer PC9 cells and do not have known resistance mechanisms including EGFR mutation T790M. We found increased expression of Axin, a β-catenin target gene, increased phosphorylation of Akt and GSK3, accumulation of β-catenin in the cytoplasm/nucleus in PC9M2 cells. Both knockdown of β-catenin and treatment with a β-catenin inhibitor at least partially restored gefitinib sensitivity to PC9M2 cells. Lung adenocarcinoma tissues derived from gefitinib-resistant patients displayed a tendency to accumulate β-catenin in the cytoplasm. We provide a rationale for combination therapy that includes targeting of the Akt-β-catenin pathway to improve the efficacy of EGFR-TKIs.

UR - http://www.scopus.com/inward/record.url?scp=84939440102&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84939440102&partnerID=8YFLogxK

U2 - 10.1038/srep13076

DO - 10.1038/srep13076

M3 - Article

C2 - 26268703

AN - SCOPUS:84939440102

VL - 5

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

M1 - 13076

ER -